a few people working at a table

Press Releases

Ladenburg Acts as Exclusive Placement Agent in the $2.5 Million Warrant Exercise Transaction for Palisade Bio, Inc.

Transaction Information Palisade Bio, Inc. (Nasdaq: PALI) ("Palisade" or the "Company") announced an agreement...

Ladenburg Thalmann Acts as Sole Book-Running Manager in $6 Million Underwritten Public Offering for Biodexa Pharmaceuticals PLC

Transaction Information Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) announced the closing of an underwritten public...

Ladenburg Thalmann Acts as Exclusive Financial Advisor to Aileron Therapeutics, Inc. (ALRN) in its Acquisition of Lung Therapeutics, Inc.

On October 31, 2023, Aileron Therapeutics, Inc. (NASDAQ: ALRN) announced the completion of its acquisition of Lung...

Ladenburg Thalmann acts as Lead Bookrunner for Carlyle Credit Income Fund on its Series A Term Preferred Offering of $30 Million

Ladenburg Thalmann served as Lead Bookrunner for this offering. Since 2017, Ladenburg has led 53 fixed income...

Ladenburg Acts as Exclusive Placement Agent in $28 Million Private Placement for enVVeno Medical

Transaction Information enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company") announced that...

Ladenburg Thalmann Acts as Sole Book-Running Manager in $4.378 Million Underwritten Public Offering for Intelligent Bio Solutions Inc.

Transaction Information Intelligent Bio Solutions Inc. (Nasdaq: INBS) (the "Company") announced the closing of...

Ladenburg Thalmann Acts as Joint Book-Running Manager for Sonnet BioTherapeutics in its $4.55 Million Follow-On Offering

Transaction Information Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) announced the closing of a follow-on...

Ladenburg Thalmann Acts as Exclusive Placement Agent in $2 Million Private Placement for Coeptis Therapeutics

Transaction Information Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the Company") announced...

Ladenburg Thalmann Acts as Exclusive Financial Advisor to Ocular Therapeutix, Inc. (Nasdaq: OCUL) in its $82.5 Million Non-Dilutive Financing

Transaction Information Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular Therapeutix", or "the Company), a...